Gotowa bibliografia na temat „ERYTHROPOIETIC DIFFERENTIATION”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „ERYTHROPOIETIC DIFFERENTIATION”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "ERYTHROPOIETIC DIFFERENTIATION"
1
Piperno, Alberto, Stefania Galimberti, Raffaella Mariani, Sara Pelucchi, Giulia Ravasi, Carolina Lombardi, Grzegorz Bilo i in. "Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project". Blood 117, nr 10 (10.03.2011): 2953–59. http://dx.doi.org/10.1182/blood-2010-08-299859.
Pełny tekst źródłaStreszczenie:
AbstractIron is tightly connected to oxygen homeostasis and erythropoiesis. Our aim was to better understand how hypoxia regulates iron acquisition for erythropoiesis in humans, a topic relevant to common hypoxia-related disorders. Forty-seven healthy volunteers participated in the HIGHCARE project. Blood samples were collected at sea level and after acute and chronic exposure to high altitude (3400-5400 m above sea level). We investigated the modifications in hematocrit, serum iron indices, erythropoietin, markers of erythropoietic activity, interleukin-6, and serum hepcidin. Hepcidin decreased within 40 hours after acute hypoxia exposure (P < .05) at 3400 m, reaching the lowest level at 5400 m (80% reduction). Erythropoietin significantly increased (P < .001) within 16 hours after hypoxia exposure followed by a marked erythropoietic response supported by the increased iron supply. Growth differentiation factor-15 progressively increased during the study period. Serum ferritin showed a very rapid decrease, suggesting the existence of hypoxia-dependent mechanism(s) regulating storage iron mobilization. The strong correlation between serum ferritin and hepcidin at each point during the study indicates that iron itself or the kinetics of iron use in response to hypoxia may signal hepcidin down-regulation. The combined and significant changes in other variables probably contribute to the suppression of hepcidin in this setting.
2
Cerdan, Chantal, Anne Rouleau i Mickie Bhatia. "VEGF-A165 augments erythropoietic development from human embryonic stem cells". Blood 103, nr 7 (1.04.2004): 2504–12. http://dx.doi.org/10.1182/blood-2003-07-2563.
Pełny tekst źródłaStreszczenie:
Abstract Combinations of hematopoietic cytokines and the ventral mesoderm inducer BMP-4 have recently been shown to augment hematopoietic cell fate of human embryonic stem cells (hESCs) during embryoid body (EB) development. However, factors capable of regulating lineage commitment of hESC-derived hematopoiesis have yet to be reported. Here we show that vascular endothelial growth factor (VEGF-A165) selectively promotes erythropoietic development from hESCs. Effects of VEGF-A165 were dependent on the presence of hematopoietic cytokines and BMP-4, and could be augmented by addition of erythropoietin (EPO). Treatment of human EBs with VEGF-A165 increased the frequency of cells coexpressing CD34 and the VEGF-A165 receptor KDR, as well as cells expressing erythroid markers. Although fetal/adult globins were unaffected, VEGF-A165 induced the expression of embryonic zeta (ζ) and epsilon (ϵ) globins, and was accompanied by expression of the hematopoietic transcription factor SCL/Tal-1. In addition to promoting erythropoietic differentiation from hESCs, the presence of VEGF-A165 enhanced the in vitro self-renewal potential of primitive hematopoietic cells capable of erythroid progenitor capacity. Our study demonstrates a role for VEGF-A165 during erythropoiesis of differentiating hESCs, thereby providing the first evidence for a factor capable of regulating hematopoietic lineage development of hESCs.
3
Socolovsky, Merav, Hyung-song Nam, Mark D. Fleming, Volker H. Haase, Carlo Brugnara i Harvey F. Lodish. "Ineffective erythropoiesis in Stat5a−/−5b−/− mice due to decreased survival of early erythroblasts". Blood 98, nr 12 (1.12.2001): 3261–73. http://dx.doi.org/10.1182/blood.v98.12.3261.
Pełny tekst źródłaStreszczenie:
Abstract Erythropoietin (Epo) controls red cell production in the basal state and during stress. Epo binding to its receptor, EpoR, on erythroid progenitors leads to rapid activation of the transcription factor Stat5. Previously, fetal anemia and increased apoptosis of fetal liver erythroid progenitors were found in Stat5a−/−5b−/− mice. However, the role of Stat5 in adult erythropoiesis was not clear. The present study shows that some adult Stat5a−/−5b−/− mice have a near-normal hematocrit but are deficient in generating high erythropoietic rates in response to stress. Further, many adult Stat5a−/−5b−/− mice have persistent anemia despite a marked compensatory expansion in their erythropoietic tissue. Analysis of erythroblast maturation in Stat5a−/−5b−/− hematopoietic tissue shows a dramatic increase in early erythroblast numbers, but these fail to progress in differentiation. Decreased expression of bcl-xLand increased apoptosis in Stat5a−/−5b−/−early erythroblasts correlate with the degree of anemia. Hence, Stat5 controls a rate-determining step regulating early erythroblast survival.
4
Hopfer, Olaf Joachim, Martina Komor, Claudia Freitag, Maximilian Mossner, Dieter Hoelzer, Eckhard Thiel i Wolf-Karsten Hofmann. "Epigenetic Dysregulation of GATA1 but Not Downstream Notch Effectors is Involved in MDS Dyserythropoiesis." Blood 112, nr 11 (16.11.2008): 1652. http://dx.doi.org/10.1182/blood.v112.11.1652.1652.
Pełny tekst źródłaStreszczenie:
Abstract Myelodysplastic syndromes (MDS) are mainly characterized by dyserythropoiesis resulting in anemia. So far, this pathological hallmark is incompletely understood. Notch signalling has recently been linked to impaired erythropoiesis and megakaryopoiesis of CD34+ progenitor cells, however its role in MDS is unclear. On the other hand, in MDS demethylating therapy results in decreased transfusion dependency, indicating aberrant methylation of key erythroid genes. Therefore, we have analyzed Notch pathway elements and its association with the key erythroid factors GATA1 and BCLxl and examined the methylation of CpGs flanking cis-regulatory elements (including N-box suppressor binding site for HES1 and GATA box) of the GATA1 erythroid promoter in differentiating CD34+ cells selected from MDS patients. We have generated an in-vitro model of MDS lineage-specific hematopoietic differentiation by culturing CD34+ bone marrow cells from healthy donors (n=7) and MDS patients (low risk: RA/n=6, RARS/n=3; high risk: RAEB/n=4, RAEB-T/n=2) with EPO. Cell harvest was at days 0, 4, 7 and 11. RNA-expression of GATA1, BCLxl, DLK1, Notch1, HES1 and HERP2 was measured by real time RT-PCR (qPCR). GPI was used as a housekeeping gene. DNA methylation at 7 CpGs of the GATA1 gene promoter was quantitatively analyzed by Pyrosequencing (Pyro Mark ID, Biotage, Uppsala, Sweden) of bisulfite treated genomic DNA at any specific time point. In normal erythropoietic cells, RNA expression of GATA1 and of BCLxl was steadily up regulated, particularly during late erythropoietic differentiation. In contrast, during MDS erythropoiesis a loss of typical up regulation of GATA1 (day 11: 2.08 vs. 0.11; p=0.001) and BCLxl (day 11: 7.46 vs. 0.16; p=0.0005) was observed. Notch ligand DLK1 showed increased expression during erythropoiesis particularly in high risk MDS as compared to normal controls (days 4–11: 0.38 vs. 0.03; p=0.02). Furthermore, expression of HES1 was increasing during the course of normal erythropoietic differentiation but not in lineage specific cells from MDS patients (day 11: 0.01 vs. 0.006; p=0.1). No hypomethylation of CpGs flanking repressor HES1 binding site within the 5′-GATA region was detected in MDS erythropoiesis. Interestingly, decremental GATA1 promotor methylation values were seen during normal erythropoiesis matching GATA1 RNA up regulation in contrast to MDS erythropoiesis (day 11: 26% vs. 58%; p=0.00004). Our data show that the critical erythropoietic transcription factor GATA1 as well as the antiapoptotic molecule BCLxl fail to be up regulated during MDS erythropoiesis. The higher residual 5′-GATA1 methylation values in MDS erythropoiesis but decremental loss thereof in normal erythropoiesis suggests a gene dose effect for GATA1 during erythropoiesis being finely tuned by CpG methylation. Its dysregulation may contribute to the ineffective erythropoiesis observed in MDS. However, a transcriptional activation of the Notch pathway leading to increased expression of the GATA1 repressor HES1 and a hypomethylation of its binding site could not be detected in MDS.
5
Colancecco, Alessandra, Luisa Ronzoni, Lorena Duca, Laura Sonzogni, Isabella Nava, Giovanna Graziadei i Maria Domenica Cappellini. "In Vitro GDF15 Expression During Thalassemic Erythroid Differentiation and Maturation". Blood 118, nr 21 (18.11.2011): 5285. http://dx.doi.org/10.1182/blood.v118.21.5285.5285.
Pełny tekst źródłaStreszczenie:
Abstract Abstract 5285 INTRODUCTION: The growth differentiation factor-15 (GDF-15), a member of the transforming growth factor-β superfamily, is thought to be related to ineffective or apoptotic erythropoiesis. GDF-15 levels were found to be significantly elevated in sera of patients with β thalassemia major (TM), however little is known about the GDF15 expression during thalassemic erythropoiesis. Non-transfusion dependent thalassemia intermedia (NTDT) represents the model of thalassemic erythropoiesis not affected by transfusions. AIM: To determine the GDF15 gene expression profile during normal and thalassemic erythroid differentiation in standard cultures and under different iron conditions, from CD34+ of normal and thalassemia intermedia subjects. METHODS: After informed consent, the CD34+ cells were obtained from peripheral blood of healthy volunteers and from patients with NTDT by positive selection using anti-CD34-tagged magnetic beads and cultured for 14 days with a medium containing stem cell factor (SCF), interleukin 3 (IL-3) and erythropoietin to induce erythroid differentiation. Each culture was split in 3 flasks: standard condition, with addition of deferoxamine (DFO 4 mM) as iron chelating agent and ferric ammonium citrate (FAC 100 mM) at day 0 of culture. The expression profiling of GDF15 gene was evaluated at baseline, day 7 and day 14 by real-time PCR (2̂-dCt). GDF15 concentrations in culture supernatants were also evaluated by enzyme-linked immunosorbent assay using DuoSet Sandwich ELISA Kit (R&D Systems, Minneapolis, MN). RESULTS: GDF15 expression and secretion increased significantly during erythroid differentiation either in normal and in NTDT cultures. At day 14 in thalassemia intermedia cultures GDF15 expression as well as the concentrations in supernatant were higher (althoug not statistically significant) compared to control (Table 1). At day 14 in control cultures GDF15 expression is up-regulated by DFO and down-regulated by FAC addition. In NTDT GDF15 expression was influenced by iron addition in cultures, but was not increased by iron depletion (Table 2). CONCLUSIONS: GDF15 levels in erythroid cultures are related to the erythropoietic stage of differentiation. In NTDT cultures the GDF15 gene profile and protein levels in supernatants are higher than in normal cultures. GDF15 levels seem to be modulated by iron in normal cultures whereas in NTDT cultures they seem to be independent from iron availability. This in vitro study supports that signals different than iron, such as erythropoietic stress, could be the major factor regulating GDF15 expression. Disclosures: No relevant conflicts of interest to declare.
6
Dumitriu, Bogdan, Michael R. Patrick, Jane P. Petschek, Srujana Cherukuri, Ursula Klingmuller, Paul L. Fox i Véronique Lefebvre. "Sox6 cell-autonomously stimulates erythroid cell survival, proliferation, and terminal maturation and is thereby an important enhancer of definitive erythropoiesis during mouse development". Blood 108, nr 4 (15.08.2006): 1198–207. http://dx.doi.org/10.1182/blood-2006-02-004184.
Pełny tekst źródłaStreszczenie:
Abstract Erythropoiesis, the essential process of hematopoietic stem cell development into erythrocytes, is controlled by lineage-specific transcription factors that determine cell fate and differentiation and by the hormone erythropoietin that stimulates cell survival and proliferation. Here we identify the Sry-related high-mobility-group (HMG) box transcription factor Sox6 as an important enhancer of definitive erythropoiesis. Sox6 is highly expressed in proerythroblasts and erythroblasts in the fetal liver, neonatal spleen, and bone marrow. Mouse fetuses and pups lacking Sox6 develop erythroid cells slowly and feature misshapen, short-lived erythrocytes. They compensate for anemia by elevating the serum level of erythropoietin and progressively enlarging their erythropoietic tissues. Erythroid-specific inactivation of Sox6 causes the same phenotype, demonstrating cell-autonomous roles for Sox6 in erythroid cells. Sox6 potentiates the ability of erythropoietin signaling to promote proerythroblast survival and has an effect additive to that of erythropoietin in stimulating proerythroblast and erythroblast proliferation. Sox6 also critically facilitates erythroblast and reticulocyte maturation, including hemoglobinization, cell condensation, and enucleation, and ensures erythrocyte cytoskeleton long-term stability. It does not control adult globin and erythrocyte cytoskeleton genes but acts by stabilizing filamentous actin (F-actin) levels. Sox6 thus enhances erythroid cell development at multiple levels and thereby ensures adequate production and quality of red blood cells.
7
Labbaye, C., M. Valtieri, U. Testa, A. Giampaolo, E. Meccia, P. Sterpetti, I. Parolini, E. Pelosi, D. Bulgarini i YE Cayre. "Retinoic acid downmodulates erythroid differentiation and GATA1 expression in purified adult-progenitor culture". Blood 83, nr 3 (1.02.1994): 651–56. http://dx.doi.org/10.1182/blood.v83.3.651.651.
Pełny tekst źródłaStreszczenie:
Abstract All-trans retinoic acid (RA) is an important morphogen in vertebrate development, a normal constituent in human adult blood and is also involved in the control of cell growth and differentiation in acute promyelocytic leukemia. We have examined the effects of RA on normal hematopoiesis by using early hematopoietic progenitor cells (HPC) stringently purified from adult peripheral blood. In clonogenetic fetal calf serum-supplemented (FCS+) or -nonsupplemented (FCS-) culture treated with saturating levels of interleukin-3 (IL-3) granulocyte- macrophage colony-stimulating factor (GM-CSF) and erythropoietin (Ep) (combined with c-kit ligand in FCS(-)-culture conditions), RA induces a dramatic dose-dependent shift from erythroid to granulomonocytic colony formation, the latter colonies being essentially represented by granulocytic clones. This shift is apparently not caused by a recruitment phenomenon, because in FCS+ culture, the total number of colonies is not significantly modified by RA addition. In FCS- liquid- suspension culture supplemented with saturating Ep level and low-dose IL-3/GM-CSF, adult HPC undergo unilineage erythropoietic differentiation: Here again, treatment with high-dose RA induces a shift from the erythroid to granulocytic differentiation pathway. Studies on RA time-response or pulse treatment in semisolid or liquid culture show that early RA addition is most effective, thus indicating that early but not late HPC are sensitive to its action. We then analyzed the expression of the master GATA1 gene, which encodes a finger transcription factor required for normal erythroid development; addition of RA to HPC stimulated into unilineage erythropoietic differentiation in liquid culture caused a virtually complete inhibition of GATA1 mRNA induction. These results indicate that RA directly inhibits the erythroid differentiation program at the level of early adult HPC, and may lead to a shift from the erythroid to granulocytic differentiation pathway. This phenomenon is correlated with inhibition of GATA1 induction in the early stages of erythropoietic differentiation.
8
Labbaye, C., M. Valtieri, U. Testa, A. Giampaolo, E. Meccia, P. Sterpetti, I. Parolini, E. Pelosi, D. Bulgarini i YE Cayre. "Retinoic acid downmodulates erythroid differentiation and GATA1 expression in purified adult-progenitor culture". Blood 83, nr 3 (1.02.1994): 651–56. http://dx.doi.org/10.1182/blood.v83.3.651.bloodjournal833651.
Pełny tekst źródłaStreszczenie:
All-trans retinoic acid (RA) is an important morphogen in vertebrate development, a normal constituent in human adult blood and is also involved in the control of cell growth and differentiation in acute promyelocytic leukemia. We have examined the effects of RA on normal hematopoiesis by using early hematopoietic progenitor cells (HPC) stringently purified from adult peripheral blood. In clonogenetic fetal calf serum-supplemented (FCS+) or -nonsupplemented (FCS-) culture treated with saturating levels of interleukin-3 (IL-3) granulocyte- macrophage colony-stimulating factor (GM-CSF) and erythropoietin (Ep) (combined with c-kit ligand in FCS(-)-culture conditions), RA induces a dramatic dose-dependent shift from erythroid to granulomonocytic colony formation, the latter colonies being essentially represented by granulocytic clones. This shift is apparently not caused by a recruitment phenomenon, because in FCS+ culture, the total number of colonies is not significantly modified by RA addition. In FCS- liquid- suspension culture supplemented with saturating Ep level and low-dose IL-3/GM-CSF, adult HPC undergo unilineage erythropoietic differentiation: Here again, treatment with high-dose RA induces a shift from the erythroid to granulocytic differentiation pathway. Studies on RA time-response or pulse treatment in semisolid or liquid culture show that early RA addition is most effective, thus indicating that early but not late HPC are sensitive to its action. We then analyzed the expression of the master GATA1 gene, which encodes a finger transcription factor required for normal erythroid development; addition of RA to HPC stimulated into unilineage erythropoietic differentiation in liquid culture caused a virtually complete inhibition of GATA1 mRNA induction. These results indicate that RA directly inhibits the erythroid differentiation program at the level of early adult HPC, and may lead to a shift from the erythroid to granulocytic differentiation pathway. This phenomenon is correlated with inhibition of GATA1 induction in the early stages of erythropoietic differentiation.
9
Wiles, M. V., i G. Keller. "Multiple hematopoietic lineages develop from embryonic stem (ES) cells in culture". Development 111, nr 2 (1.02.1991): 259–67. http://dx.doi.org/10.1242/dev.111.2.259.
Pełny tekst źródłaStreszczenie:
When embryonic stem cells are cultured directly in semisolid media (methyl cellulose), they proliferate and differentiate to generate colonies known as embryoid bodies (EBs). These EBs consist of differentiated cells from a number of lineages including those of the hematopoietic system. Following 10 days of culture in the presence of 10% fetal calf serum, more than 40% of all EBs from three different ES cell lines, CCEG2, D3 and SQ1.2S8 contained visible erythropoietic cells (i.e. red with hemoglobin). Beta H1 (z globin) mRNA is detectable in EBs within 5 days of differentiation, whilst beta(maj)-globin RNA appears by day 6. In the presence of erythropoietin (Epo), the frequency of EBs with erythropoietic activity increases to greater than 60%; Epo also prolongs this erythropoietic activity. Interleukin-3 (IL-3) does not significantly increase the frequency of EBs that contain erythroid cells, but increases slightly the number of erythropoietic cells associated with them. In the presence of IL-3, in addition to cells of the erythroid lineage, macrophages, mast cells and in some instances neutrophils are found within differentiating EBs. The development of macrophages is significantly enhanced by the addition of IL-3 alone or in combination with IL-1 and M-CSF or GM-CSF. When well-differentiated EBs are allowed to attach onto tissue-culture plates and grown in the presence of IL-3, a long-term output of cells from the mast cell lineage is observed.(ABSTRACT TRUNCATED AT 250 WORDS)
10
Hopfer, Olaf J., Martina Komor, Ina S. N. Koehler, Claudia Freitag, Dieter Hoelzer, Eckhard Thiel i Wolf-Karsten Hofmann. "GATA and BCLxl Downregulation in Erythropoiesis during In Vitro Lineage Specific Differentiation of MDS Hematopoietic Progenitor Cells Is Not Induced by Activated Notch Pathway." Blood 110, nr 11 (16.11.2007): 4118. http://dx.doi.org/10.1182/blood.v110.11.4118.4118.
Pełny tekst źródłaStreszczenie:
Abstract Notch signals have recently been shown to inhibit erythroid and megakaryocytic differentiation of hematopoietic progenitor cells. In myelodysplastic syndrome (MDS) its role in dyserythropoiesis has not been fully elucidated. Therefore we asked whether dysregulation of Notch pathway elements might be associated with impaired GATA1 and BCLxl expression and ineffective erythropoiesis being a hallmark of MDS hematopoiesis. We have generated an in-vitro model of MDS lineage-specific hematopoietic differentiation by culturing CD34+ bone marrow cells from healthy donors (n=7) and MDS patients (low risk: RA/n=6, RARS/n=3; high risk: RAEB/n=4, RAEB-T/n=2) with EPO and TPO. Cell harvest was at days 0, 4, 7 and 11. Expression of GATA1, BCLxl, DLK1, Notch1, HES1 and HERP2 was measured by real time RT-PCR (qPCR). RNA expression of GATA1 and of BCLxl was steadily upregulated, particularly during late normal erythropoiesis. During normal megakaryopoiesis expression of both genes was up to 50 times lower as compared to normal erythropoiesis. In contrast, during MDS erythropoiesis a loss of typical late upregulation of GATA1 and BCLxl was observed. DLK1 expression during erythropoiesis showed increased expression particularly in high risk MDS vs. normal controls. Expression of HES1 was increasing during the course of normal erythropoietic and megakaryopoietic differentiation but not in lineage specific cells from MDS patients. In conclusion our data show that the central erythropoietic transcription factor GATA1 and the associated antiapoptotic molecule BCLxl are markedly downregulated during MDS erythropoiesis which may contribute to the ineffective erythropoiesis seen in this disease. Increased DLK1 expression in differentiated stem cells from high risk MDS patients was seen. However, an upregulation of the Notch pathway leading to increased expression of the GATA1 repressor HES1 could not be detected.
Rozprawy doktorskie na temat "ERYTHROPOIETIC DIFFERENTIATION"
1
Zhang, Ji. "Mechanisms of erythroid proliferation and differentiation analysis of the role of erythropoietin receptor in the friend virus model /". View the abstract Download the full-text PDF version (on campus access only), 2008. http://etd.utmem.edu/ABSTRACTS/2008-025-JiZhang-index.html.
Pełny tekst źródłaStreszczenie:
Thesis (Ph.D. )--University of Tennessee Health Science Center, 2008.Title from title page screen (viewed on October 7, 2008 ). Research advisor: Paul A. Ney, M.D. Document formatted into pages (xi, 122 p. : ill.). Vita. Abstract. Includes bibliographical references (p. 78-110).
2
Dobocan, Monica Crisanti. "Chaperonin 10: an endothelial-derived, erythropoietin- dependent differentiation factor". Thesis, McGill University, 2009. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=40690.
Pełny tekst źródłaStreszczenie:
Erythropoietin (EPO) stimulates endothelial cells to produce various factors that support the formation of erythroid cells. We identified by 2D electrophoresis/mass spectrometry one such factor as being chaperonin 10 (cpn10). Cpn10 was released in human umbilical vein endothelial cells (HUVEC) medium after EPO treatment; it decreased the proliferation of the erythroleukemic K562 cells, while stimulating differentiation in the erythroid TF-1 cells and skin fibroblasts. We analyzed the early events initiated by the addition of cpn10 in K562 and TF-1 cells and found significant changes in the phosphorylation levels of glycogen synthase kinase 3 (GSK-3) and cofilin-1. Further experiments using GSK-3 inhibitors in the presence or absence of cpn10 showed an alteration in the proliferation and differentiation patterns previously observed in TF-1 cells, suggesting a possible role for GSK-3 in cell differentiation as part of the signal transduction pathway triggered by cpn10. This is the first evidence linking cpn10 to erythropoiesis.L’érythropoïétine (EPO) stimule les cellules endothéliales à produire différents facteurs qui soutiennent la formation des érythrocytes. En effectuant une électrophorèse-2D / spectrométrie de masse, on a identifié la chapéronine10 (cpn10) comme étant un de ces facteurs. Cpn10 est secrétée par les cellules endothéliales HUVEC après un ajout d’EPO; elle diminue la prolifération des cellules érythroleucémiques K562 et elle stimule la différentiation des érythrocytes TF-1 et des fibroblastes. On a observé qu’une des actions immédiates initiées par cpn10 dans les cellules K562 et TF-1 était de changer significativement la phosphorylation de GSK-3 (glycogen synthase kinase 3) et cofilin-1. Des inhibiteurs de GSK-3 utilisés en présence de cpn10 ou seuls ont altéré le processus de prolifération et différentiation observés auparavant avec les cellules TF-1, en suggérant ainsi que GSK-3 puisse jouer un rôle dans la différentiation cellulaire déclenchée par cpn10. C’est la première fois qu’un lien est décrit entre cpn10 et l’érythropoïèse.
3
Raimbault, Anna. "Le ribosome au cours de l'érythropoïèse". Thesis, Sorbonne Paris Cité, 2016. http://www.theses.fr/2016USPCB251.
Pełny tekst źródłaStreszczenie:
La biogenèse du ribosome est un processus indispensable à la prolifération cellulaire car elle permet la synthèse protéique assurant la croissance avant la division cellulaire. Les ribosomopathies telles que le syndrome myélodysplasique 5q- et l’anémie de Blackfan-Diamond sont dues respectivement à une mutation d’un gène codant une protéine ribosomique (RP) et à l’haploinsuffisance en RPS14, RP de la petite sous-unité du ribosome. Les patients atteints de l’une de ces ribosomopathies présentent un défaut de l’érythropoïèse suggérant que celle-ci est particulièrement dépendante du ribosome. L’érythropoïèse est le processus qui permet la formation de globules rouges à partir de cellules souches hématopoïétiques et consiste en différents stades de différenciation appelés érythroblastes. C’est dans ce contexte que je me suis intéressée au ribosome au cours de l’érythropoïèse. Dans un premier temps, nous avons caractérisé la biogenèse du ribosome dans des cellules érythroïdes primaires humaines et murines. Pour cela nous avons adapté une technique de SILAC pulsé et mis au point la ribomique, technique de protéomique permettant l’analyse de la biogenèse du ribosome dans des échantillons de cellules primaires basée sur l’identification presque exhaustive des protéines ribosomiques. À l’aide de la ribomique et par d’autres techniques, nous avons mis en évidence une diminution de la biogenèse du ribosome après le stade érythroblaste basophile. Nous avons également montré que cette biogenèse du ribosome est en partie sous le contrôle de la voie mTORC1 régulée par les deux cytokines fondamentales de l’érythropoïèse : le Stem Cell Factor (SCF) et l’érythropoïétine (EPO). L’expression par l’érythroblaste des récepteurs des deux cytokines permet une biogenèse du ribosome optimale. L’inhibition de la biogenèse du ribosome par le CX-5461, inhibiteur spécifique de l’ARN polymérase I, ou par la rapamycine, inhibiteur de mTORC1, entraîne une accélération de la différenciation érythroïde soulignant un rôle de la biogenèse du ribosome au cours de l’érythropoïèse. L’inhibition de la voie mTORC1 modifie l’ordre de clivage de l’ARNr, reflet d’une modification de sa maturation. Les expériences de ribomique dans les érythroblastes humains ont également permis de mettre en évidence la présence de paralogues de RP et la sous-représentation de certaines RPs au sein des ribosomes suggérant une hétérogénéité des ribosomes dans les érythroblastes humains. Parallèlement, un modèle mimant le syndrome 5q- a été développé par une approche shRPS14 dans une lignée humaine érythroleucémique dépendante de l’EPO. L’inhibition de RPS14 entraîne un défaut de biogenèse de la sous-unité 40S du ribosome aboutissant à une diminution des ribosomes entiers formés et une diminution de la traduction globale. Cependant une traduction est maintenue. Le défaut de biogenèse de la sous-unité 40S entraîne une augmentation de la quantité de c-KIT, récepteur du SCF et une diminution de la quantité de GATA1, facteur de transcription spécifique de l’érythropoïèse. Nous avons mis en évidence que la diminution de GATA1 est due à une diminution de sa traduction tandis que la traduction d’autres protéines est conservée dans ce contexte d’altération de la biogenèse du ribosome. Nous avons ensuite réalisé une analyse des transcrits présents dans les fractions polysomales correspondants à la traduction la plus efficace. Nous avons montré grâce à ce traductome que les propriétés thermodynamiques des parties 5’ et 3’UTR des ARNm modulent leur traduction dans le contexte d’inhibition de RPS14. Ces données suggèrent que l’altération de la biogenèse du ribosome peut aboutir à une modification du programme traductionnel. Ce travail montre que la biogenèse du ribosome diminue au cours de l’érythropoïèse et participe à la différenciation érythroïde. La voie mTORC1 participe au contrôle de cette biogenèseRibosome biogenesis is a key event allowing cell growth before division. Defective RB recognized in ribosomopathyinherited Diamond-Blackfan anemia and 5q- syndrom. In this study, we aimed at investigating the regulatory role of RB during the erythroid precursor maturation which is characterized by a cell size reduction during 2 to 3 rapid cell divisions. We used two in vitro systemsé of expansion and differentiation of erythroblasts (E.) derived of immature hematopoietic progenitors from human mobilized peripheral blood or mouse fetal liver. The expansion step is supported by the Stem Cell Factor (SCF) and the second step depends on erythropoietin (EPO). The structure of the nucleolus was studied by electron microscopy. Compared to immature proerythroblasts (proE), a dramatic size reduction and change in nucleolar structure (ie. the disappearance of fibrillar and dense fibrillar components) is observed at the stage of mature polychromatophilic E. suggesting a loss of functionality. RB was measured by a pulsed SILAC (Stable Isotopic Labeling by Amino acids in Culture cell) proteomic assay that quantified the incorporation of newly synthesized ribosomal proteins in the ribosome. Both in mouse and human models, immature proE expanded upon SCF and EPO demonstrate a maximal RB with a renewal rate of 60% and 50% every 14h and 24h, respectively. By contrast, RB rapidly interrupted with the disappearance of proE and basophilic E after the switch to EPO alone. Consistently, the quantities of ribosomal RNA (rRNA) 45S precursor estimated by qPCR are maximal in proE and almost null in orthochromatophilic E. Inhibition of RB at proE stage by RNApol I specific inhibitor (CX-5461) accelerates the onset of terminal erythroid differentiation suggesting that RB is a rate limiting factor for final maturation. We then hypothesize that degree of signaling intensity in response to SCF and EPO may control the level of RB. To address this question, we investigated the mTORC1 (mechanistic Target Of Rapamycin Complex 1) pathway which is directly involved in RB through its substrate p70S6Kinase. Activation of P-p70S6Kinase and P-Rps6, as well as ribosome renewal, are twice more elevated in response to SCF and EPO than to EPO alone. Furthermore, inhibition of mTORC1/p70S6K/Rps6 pathway by rapamycin disrupts RB and leads to an acceleration of terminal erythroid differentiation.This study demonstrates that the collapse of RB promotes erythroid cell terminal maturation and shows the regulatory role of mTORC1 pathway on RB during erythropoiesis
4
Bin, Sofia <1990>. "Erythropoietin reduces pathogenic humoral immunity by inhibiting T Follicular Helper cell differentiation and function". Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2021. http://amsdottorato.unibo.it/9694/1/TesiPhD_SofiaBin_Final.pdf.
Pełny tekst źródłaStreszczenie:
A large fraction of organ transplant recipients develop anti-donor antibodies (DSA), with accelerated graft loss and increased mortality. We tested the hypothesis that erythropoietin (EPO) reduces DSA formation by inhibiting T follicular helper (TFH) cells.
We measured DSA levels, splenic TFH, TFR cells, germinal center (GC), and class switched B cells, in murine models of allogeneic sensitization, allogeneic transplantation and in parent-to-F1 models of graft versus host disease (GVHD).
We quantified the same cell subsets and specific antibodies, upon EPO or vehicle treatment, in wild type mice and animals lacking EPO receptor selectively on T or B cells, immunized with T-independent or T-dependent stimuli.
In vitro, we tested the EPO effect on TFH induction. We isolated TFH and TFR cells to perform in vitro assay and clarify their role.
EPO reduced DSA levels, GC, class switched B cells, and increased the TFR/TFH ratio in the heart transplanted mice and in two GVHD models.
EPO did also reduce TFH and GC B cells in SRBC-immunized mice, while had no effect in TNP-AECM-FICOLL-immunized animals, indicating that EPO inhibits GC B cells by targeting TFH cells. EPO effects were absent in T cells EPOR conditional KO mice, confirming that EPO affects TFH in vivo through EPOR.
In vitro, EPO affected TFH induction through an EPO-EPOR-STAT5-dependent pathway.
Suppression assay demonstrated that the reduction of IgG antibodies was dependent on TFH cells, sustaining the central role of the subset in this EPO-mediated mechanism.
In conclusion, EPO prevents DSA formation in mice through a direct suppression of TFH. Development of DSA is associated with high risk of graft rejection, giving our data a strong rationale for studies testing the hypothesis that EPO administration prevents their formation in organ transplant recipients. Our findings provide a foundation for testing EPO as a treatment of antibody mediated disease processes.
5
Vieillevoye, Maud. "Role and expression of transferrin receptor 2 in erythropoiesis". Thesis, Paris 5, 2013. http://www.theses.fr/2013PA05S020.
Pełny tekst źródłaStreszczenie:
L’érythropoïèse est le processus de différentiation d’un progéniteur érythroïde multipotent en globules rouges. La différentiation érythroïde est essentiellement contrôlée par le récepteur à l’érythropoïétine (EPOR). Nous avons montré que le récepteur à la transferrine de type 2 (TFR2) est un membre important du complexe formé par l’EPOR. Le TFR2 présente, comme l’EPOR une expression restreinte qui dépend du type cellulaire. Ainsi son expression n’a pu être détectée que dans le foie, l’érythron et l’intestin grêle. Le rôle du TFR2 a été exploré dans les hépatocytes et il a été montré qu’il joue le rôle d’un senseur de fer dans cette lignée et de ce fait contribue à l’homéostasie du fer. Nous avons déterminé le rôle du TFR2 dans les érythroblastes et montré que TFR2 est une protéine escorte de l’EPOR qui contribue à l’érythropoïèse in vitro et in vivo. De plus, nos travaux montrent que le TFR2 est requis pour la production de GDF15 (Growth Differentiation Factor 15) dans les érythroblastes. D’autre part nous avons démontré que la production de GDF15 est augmentée par l’EPO, la déplétion intracellulaire en fer et l’activité transactivatrice de P53. L’inhibition de l’expression de P53, réalisée au cours de l’étude de son rôle dans la production de GDF15, a révélé son implication dans l’érythropoïèse normale. Nous avons mis en évidence l’existence de plusieurs formes du TFR2. Deux d’entre elles résultent de l’utilisation de sites distincts d’initiation de la traduction. Ces deux isoformes sont régulée différemment au cours de la maturation des érythroblastes. La troisième isoforme, appelée TFR2 soluble (sTFR2), est relargée dans le plasma suite au clivage du TFR2. Nous avons montré que la production du sTFR2 est inhibée en présence du ligand de TFR2, la transferrine saturée en fer (holoTF) alors que le TFR2 est stabilisé dans ces mêmes conditions. Les rôles spécifiques des trois formes du TFR2 doivent encore être élucidésErythropoiesis is the differentiation process of a multipotent erythroid progenitor into red blood cells. Erythroid differentiation is primarily controlled by the erythropoietin receptor (EPOR). We showed that the Transferrin receptor 2 (TFR2) is an important member of the EPOR complex. TFR2 has like EPOR a lineage-restricted expression and can solely be detected in the liver, erythron and small intestine. TFR2 function has been explored in hepatocytes where it plays the role of an iron sensor and contributes to iron homeostasis. We determined the role of TFR2 in erythroblasts and showed that TFR2 is an escort protein for EPOR that contributes to optimal erythropoiesis in vitro and in vivo. Moreover we evidenced that TFR2 is absolutely required for the production of Growth differentiation factor 15 (GDF15) in erythroblasts. We further demonstrated that GDF15 production is increased by EPO levels, by intracellular iron depletion as well as by P53 trans-activation activity. The inhibition of P53 expression, realized for the study of its role in GDF15 production, revealed its implication in normal erythropoiesis. We evidenced that TFR2 is expressed under several forms, two of which result from the utilization of distinct translational initiation sites. These two isoforms are differently regulated during erythroid maturation. The third form called soluble TFR2 (sTFR2) is released in the plasma after TFR2 cleavage. We showed that sTFR2 production is inhibited in the presence of TFR2 ligand, iron loaded transferrin (holoTF) whereas cell surface TFR2 expression is stabilized by holoTF. The specific roles of the three forms of TFR2 expressed by erythroblasts remain to be elucidated
6
Penglong, Tipparat. "Molecular Basis of Erythroid Cell Proliferation and Differentiation". Thesis, Paris 11, 2015. http://www.theses.fr/2015PA11T022.
Pełny tekst źródłaStreszczenie:
Pour assurer la production de milliards de globules rouges, l’érythropoièse doit parfaitement contrôler les processus de prolifération et de différenciation. Ces deux processus sont régulés par l’expression de gènes spécifiques dépendant d’une coordination entre l’activité des facteurs de transcription (FT) et les fonctions épigénétiques portées par exemple par les protéines à bromodomaine. Cette étude se concentre sur les conséquences de l’association ou la dissociation du FT clef de l’érythropoièse GATA-1 avec les FT déterminant pour le cycle cellulaire, pRb et E2F. Dans la première partie de ma thèse, j’ai participé à l’étude du rôle de l’association/dissociation de GATA-1 et FOG-2 avec pRb/E2F dans le contrôle la balance prolifération/différenciation cellulaire. Nos résultats montrent que les souris exprimant une mutation de GATA-1 sur la sérine 310 (GATA-1S310A), qui a la capacité accrue à séquestrer E2F-2, présentent une anémie létale lorsqu’un mécanisme de compensation de production de E2F-2 induit par l’IGF-1 est inhibé. Puis, nous avons trouvé que les propriétés décrites pour GATA-1 sont partagées par le FT FOG-2 et montré que l’abrogation de sa fixation avec pRb induit une perturbation de l’adiposité dans des souris FOG-2pRb-. Dans la deuxième partie, l’expression de c-Myc étant régulé différentiellement par GATA-1 et E2F, j’ai testé si la drogue « JQ1 », premier inhibiteur épigenétique chimique de l’expression de c-Myc, pouvait contrôler l’érythropoièse. Pour cela, j’ai utilisé la ligné érythroleucémique UT7 qui prolifère sans se différencier en présence d’érythropoiétine (stade proérythroblaste). Les résultats montrent que le traitement par JQ1 bloque la prolifération des cellules UT7 et permet de réinitier le programme de différentiation érythroide terminale. J’ai alors recherché les mécanismes moléculaires impliqués dans cette régulation et trouvé que l’inhibition transcriptionnelle de c-Myc par JQ1 est associée à l’inhibition de l’activité transcriptionnelle de STAT5 sans modification de son état de phosphorylation. Enfin, j’ai montré que JQ1 pouvait avoir une activité comparable à celle du TGF-b mais sans implication les voies Smad. Des études in vivo montre que JQ1 augmente la viabilité cellulaire et accélère la maturation des cellules érythroides à la fois chez les souris sauvages et thalassémiques. Cette différence d’action de JQ1 sur l’érythropoièse normale et pathologique implique des modifications épigénétiques différentielles entre ces deux types cellulaires et sont à la base de nouvelles stratégies du traitement du cancer. Le rôle clef de la régulation de l’association/dissociation de GATA-1 ou FOG-2 avec pRb/E2F dans l’érythropoièse et l’adipogénèse, nous a conduit, dans une troisième partie, à déterminer in vivo, les conséquences physiologiques de la séquestration de E2F par pRb. Pour cela nous avons crée une souris transgénique exprimant de façon conditionnelle un peptide contenant la partie N terminale de GATA-1 qui se fixe à pRb (GATA-1Nter). In vitro, ce peptide séquestre E2F dans le complexe GATA-1Nter/pRb et inhibe la prolifération cellulaire de façon irréversible. In vivo, aucune souris transgéniques exprimant le peptide GATA-1Nter n’a pu être sélectionnée et une mortalité au stade embryonnaire est observée. Une expression induite de ce peptide au stade adulte ne produit que des souris chimériques avec une fréquence de recombinaison du transgène GATA-1Nter importante. L’établissement de lignées stables de souris exprimant le peptide GATA-1Nter permettra de déterminer les conséquences physiologiques de la séquestration de E2F dans le complexe GATA-1Nter/pRbTo ensure the generation of billions of erythrocytes daily, erythropoiesis must be well controlled by proliferation and differentiation processes. These two processes are regulated by expressions of specific genes, coordinated by transcription factors (TFs) and epigenetic factors, such as bromodomain proteins. This study focused on the effects of the binding and dissociation of a key erythroid TF, GATA-1, to the crucial cell cycle TFs, pRb and E2F. In the first part of this thesis, the role of GATA-1 and FOG-2 binding to pRb/E2F in a control balances between cell proliferation and differentiation was studied. Mice bearing a GATA-1 mutation (GATA-1S310A) displayed higher levels of E2F2 sequestration and suffered from fatal anemia when the compensatory pathway of E2F2 production via IGF-1 signaling was also inhibited. The properties described for GATA-1 were found to be common to FOG-2, and the abolition of FOG-2 binding to pRb led to obesity resistance in FOG-2pRb- mice. In the second part of this work, as c-Myc is regulated by GATA-1 and E2F, the first chemical epigenetic inhibitor repressing c-Myc expression to be described, JQ1, was investigated to see if it could control erythropoiesis. The UT7 erythroleukemia cell line, which proliferates without differentiating was used. This cell line stops differentiation at the proerythroblast stage, in response to erythropoietin. JQ1 treatment inhibited UT7 proliferation and restored terminal erythroid differentiation. The molecular mechanism underlying this regulation by JQ1 was shown that the inhibition of c-Myc expression was associated with the inhibition of STAT5 transcription, with no change in the phosphorylation of this protein. It was found that JQ1 had a putative TGF--like activity, which did not involve the Smad pathway. It was shown in the ex vivo studies that JQ1 increased the viability of erythroid cells and accelerated the maturation of these cells in both WT and thalassemic mice. The observed differences between leukemic and normal erythropoiesis involved differential epigenetic modifications that could be at the basis of new strategies regarding cancer treatment.The key role of the association of GATA-1 or FOG-2 had with pRb/E2F, and the dissociation of these factors, in erythropoiesis and adipogenesis, respectively, led us to investigate, in vivo, the physiological consequences of E2F sequestration by pRb. As a result, transgenic mice displaying conditional expression of a peptide containing the N-terminal part of GATA-1 that binds to pRb (GATA-1Nter) were developed. In vitro, this peptide traps E2F in a GATA-1Nter/pRb complex, resulting in the irreversible inhibition of cell proliferation. The yield of transgenic mice expressing the GATA-1Nter peptide in vivo was unsuccessful, as this expression lead to lethality at the embryonic stage. Using an alternative approach, based on the inducible expression of the peptide in adults, chimeric mice with a high frequency of recombination of the GATA-1Nter transgene were obtained for this study. The establishment of a stable mouse line expressing the GATA-1Nter peptide should make it possible to determine the pathophysiological consequences of E2F sequestration in the GATA-1Nter/pRb complex
7
Oburoglu, Leal. "Metabolic fueling of hematopoietic stem cell differentiation to the erythroid lineage". Thesis, Montpellier 2, 2014. http://www.theses.fr/2014MON20122.
Pełny tekst źródłaStreszczenie:
Les cellules souches hématopoïétiques (CSH) possèdent deux propriétés fondamentales : l'auto-renouvellement et la capacité de se différencier en lignées hématopoïétiques de tout type. Les CSH se maintiennent dans la moelle osseuse et se renouvellent par division asymétrique. En revanche, les divisions symétriques caractérisent les cellules qui s'engagent dans la différenciation. L'environnement pauvre en oxygène de la moelle osseuse favorise la glycolyse anaérobique et l'oxydation des acides gras, préservant, respectivement, la quiescence et les divisions asymétriques. Que l'engagement des CSH vers la différenciation lymphoïde, myéloïde ou érythroïde dépende ou entraîne une reprogrammation métabolique n'est toujours pas connu. En effet, de nombreuses études ont montré que cytokines et contacts cellulaires sont indispensables pour l'engagement des CSH vers une lignée donnée, alors que l'impact potentiel des nutriments et du métabolisme sur ce processus reste très peu étudié. La différenciation est associée à une prolifération qui nécessite des besoins métaboliques accrus pouvant être supportés par diverses sources d'énergie, telles que le glucose, les acides gras, le lactate ou la glutamine. Le glucose et la glutamine sont des précurseurs de l'ATP, des lipides et des nucléotides. Toutefois, leurs contributions relatives aux voies métaboliques contrôlant l'engagement des CSH n'ont pas été évaluées. Pour autant, nos études ainsi que celles menées par d'autres laboratoires ont montré que l'expression du transporteur de glucose Glut1 n'augmente qu'au cours des dernières étapes de la différenciation érythroïde, suggérant l'implication potentiel d'autres nutriments dans la régulation des étapes précoces de l'engagement vers la voie érythroïde. Ainsi, mon travail de thèse a consisté à déterminer si la disponibilité et l'utilisation des nutriments régulent la différenciation des CSH vers la lignée érythroïde. De fait, j'ai montré que le transporteur de glutamine ASCT2 est hautement exprimé dans les CSH et que la répression d'ASCT2 ou le blocage du métabolisme de la glutamine empêche la différenciation érythroïde des CSH, les détournant vers la voie myéloïde, même en présence d'érythropoïétine. Dans ces conditions, nous avons montré que la différenciation érythroïde ne pouvait pas être restaurée par l'ajout d'intermédiaires du cycle de Krebs, alors que qu'elle était dépendante de la biosynthèse de novo de nucléotides. Étonnamment, le 2-désoxyglucose (2-DG), un analogue du glucose inhibant la glycolyse, accélérait l'érythropoïèse. Nous avons aussi mis en évidence in vivo, en condition de stress érythropoïétique, des influences différentes du catabolisme de la glutamine et celui du glucose dans la modulation de l'érythropoïèse. Afin de mieux élucider les mécanismes par lesquels la glutamine module la différenciation érythroïde des CSH, nous avons étudié les voies métaboliques qu'elle emprunte. Des expériences de suivi de la glutamine marquée ont montré que l'entrée de la glutamine dans le cycle de Krebs est requise pour une érythropoïèse efficace. Par contre, nous avons montré que la synthèse de novo des nucléotides était l'étape limitante de la différenciation érythroïde. De plus, nous avons observé que la différenciation érythroïde accélérée en présence du 2-DG était associée à une augmentation importante du niveau des pentoses phosphates, précurseurs des nucléotides. Ainsi, l'utilisation de la voie des pentoses phosphates par le glucose, plutôt que la glycolyse, était essentielle pour l'érythropoïèse. En conclusion, mon travail de thèse a montré que la production de nucléotides via le métabolisme coordonné du glucose et de la glutamine est la condition sine qua non pour l'engagement des CSH vers la lignée érythroïdeHematopoietic stem cells (HSCs) possess two fundamental characteristics; self-renewal capacity and the ability to give rise to all blood cell lineages. Before their commitment to a specific lineage, these cells are maintained in a quiescent state in the bone marrow. Asymmetric division is essential for the maintenance of the stem cell compartment while symmetric division results in HSC differentiation. The hypoxic environment of the bone marrow is conducive to anaerobic glycolysis and fatty acid oxidation, preserving stem cell quiescence and asymmetric division, respectively. However, it is not known whether the commitment of an HSC to a lymphoid, myeloid or erythroid lineage fate, is regulated by a metabolic switch. Indeed, while much research has shown a critical role for cytokines and cell-cell contacts in the commitment of HSCs to distinct hematopoietic lineages, the possibility that nutrient entry and metabolism may contribute to this process was not considered until very recently. Cell differentiation is associated with proliferation resulting in increased metabolic requirements that can be met by energy sources such as glucose, fatty acids, lactate, or glutamine, amongst others. While glucose and glutamine are both precursors for the production of ATP, lipids and nucleotides, their relative contributions to metabolic pathways driving HSC lineage commitment have not been evaluated. Interestingly, we and others previously found that the Glut1 glucose transporter is highly upregulated only during the final mitoses of HSC-driven erythroid differentiation, suggesting that other nutrients may regulate early stages of erythroid lineage commitment. During my PhD, I was interested in determining whether nutrient availability and utilization regulate HSC differentiation to the erythroid lineage. Interestingly, I found that the ASCT2 glutamine transporter is expressed at high levels on HSCs. Downregulation of ASCT2 or blocking glutamine metabolism abrogated erythroid differentiation of HSCs and diverted erythropoietin-signaled HSCs towards a myeloid fate. Under conditions where glutamine utilization was blocked, erythroid differentiation was not restored by directly replenishing the tricarboxylic acid cycle but rather, was dependent on de novo nucleotide biosynthesis. Surprisingly, 2-deoxyglucose, a glucose analogue that inhibits glycolysis, enhanced erythropoiesis. Glutamine and glucose catabolism also differentially modulated erythropoiesis in vivo, under stress conditions. To better elucidate the mechanism(s) via which glutamine supports the erythroid lineage specification of HSCs, we evaluated the metabolic pathways fueled by glutamine. Carbon/nitrogen-labeled glutamine tracing experiments showed that the rate-limiting step in EPO-induced erythroid differentiation is glutamine-dependent de novo nucleotide biosynthesis while glutamine entry into the TCA cycle (anaplerosis) is not required. Furthermore, the accelerated erythroid differentiation in the presence of 2-DG was associated with a striking increase in pentose phosphates, precursors of nucleotides. Notably, the shunting of glucose into the pentose phosphate pathway (PPP), rather than glycolysis, was essential for erythropoiesis. In conclusion, my research shows that the coordinated redirection of glucose and glutamine into the production of nucleotides is the sine qua non condition for the erythroid differentiation of HSCs
8
Romano, Manuela. "Stage-specific changes in the Krebs cycle network regulate human erythroid differentiation". Thesis, Montpellier, 2018. http://www.theses.fr/2018MONTT077.
Pełny tekst źródłaStreszczenie:
Le processus conduisant à la prolifération et différenciation des cellules souches hématopoïétiques (CSH) en cellules de toutes les lignées sanguines s’appelle l’hématopoïèse. Bien que l'engagement des CSH soit régi par les cytokines, les facteurs de transcription, les modificateurs épigénétiques et la niche des CSH, notre groupe a constaté que leur engagement vers la lignée érythroïde dépendait aussi du métabolisme de la glutamine. La glutaminolyse contribue à la biosynthèse des nucléotides de novo ainsi qu’à la production de l'alpha-kétoglutarate (αKG), intermédiaire métabolique du cycle TCA (Oburoglu et al. 2014). Il est cependant important de noter que la différenciation érythroïde est un processus unique, où chaque cellule fille est structurellement et fonctionnellement différente de sa cellule mère. Chaque division définit un stade de différenciation précis avec un dernier cycle de division produisant un réticulocyte énucléé. Ainsi, nous avons émis l'hypothèse que les réseaux métaboliques mobilisés dans les progéniteurs érythroïdes changent en fonction du stade de différenciation et que ces réseaux régulent la transition des progéniteurs d'un stade à l'autre.Au cours de ma thèse, j’ai caractérisé les états métaboliques associés aux différents stades de différenciation des progéniteurs érythroïdes. Nous avons ainsi montré qu'aux stades précoces de différenciation érythroïde, avant la différenciation terminale, les progéniteurs hématopoïétiques présentent une activité métabolique accrue avec un niveau de phosphorylation oxydative (OXPHOS) plus élevé. Ces données sont en corrélation avec l'augmentation de la génération de l’αKG à ces stades de différenciation. De plus, nous avons constaté une augmentation de l’OXPHOS de ces progéniteurs en présence d’αKG exogène. Cependant, la différenciation terminale des précurseurs érythroïdes, caractérisée par la perte de la masse mitochondriale et de leur potentiel membranaire, est associée à une diminution du niveau d'OXPHOS. Ainsi, l'administration exogène d’αKG, a fortement atténué la différenciation érythroïde terminale et l'énucléation, sans affecter la différenciation des pro-érythroblastes. Inversement, un antagoniste de l’αKG (diméthyloxalylglycine, DMOG) n'a pas altéré la différenciation terminale ou l'énucléation, malgré l'abrogation de l'OXPHOS dans les érythroblastes.Ces données suggèrent que la production d’αKG et sa contribution à l’OXPHOS perturbent l'énucléation des globules rouges. C'est pourquoi, dans le but de réduire les niveaux intracellulaires d’αKG, nous avons inhibé l’expression de l'isocitrate déshydrogénase I (IDH1), enzyme cytosolique catalysant la conversion de l'isocitrate en αKG. Cependant, comme IDH1 peut catalyser les réactions dans les deux sens, la diminution de son expression pourrait également augmenter les niveaux d’αKG. En effet, nous avons constaté que le knockdown d'IDH1 entraînait une forte atténuation de la différenciation terminale et de l'énucléation des précurseurs érythroïdes. Cet effet est probablement dû à un déséquilibre de la disponibilité des substrats ; ainsi l’administration ectopique de l’αKG ainsi que du citrate renforce l’altération de la différenciation terminale des précurseurs érythroïdes IDH1-/- ainsi que leur énucléation. Cette étude identifie donc un rôle crucial pour le métabolite αKG dans la régulation de la fonction mitochondriale et de l’OXPHOS, processus qui sont une condition sine qua non pour la différenciation des précurseurs érythroïdes au stade proérythroblaste. Nous montrons en outre que la suppression d’OXPHOS et la catalyse d’intermédiaires du TCA, substrats d’IDH1, sont requis pour les phases terminales de la différenciation érythroïde et l'énucléation.En conclusion, les résultats obtenus au cours de ma thèse mettent en évidence la nature dynamique des réseaux métaboliques qui régulent la progression des précurseurs érythroïdes tout au long des différents stades de la différenciation érythroïdeHematopoiesis is the process whereby hematopoietic stem cells (HSCs) proliferate and differentiate to all blood cell lineages. While HSC commitment is known to be regulated by cytokines, transcription factors, epigenetic modifiers and the HSC niche, our group found that specification of HSCs to the red cell lineage is dependent on glutamine metabolism. Glutaminolysis contributes to de novo nucleotide biosynthesis and to the generation of the alpha-ketoglutarate (αKG) TCA cycle metabolite (Oburoglu et al. 2014). Importantly though, erythroid differentiation is a unique process as each daughter cell is structurally and functionally different from its parent cell. Each division defines a stage of differentiation with the final division cycle resulting in the production of an enucleated reticulocyte which further matures to a biconcave erythrocyte. Thus, we hypothesized that progenitor metabolic networks change as a function of the erythroid differentiation stage and moreover, that they regulate the transition of progenitors from one stage of differentiation to the next.During my PhD, I assessed the metabolic alterations that occur as a function of the erythroid differentiation stage. We showed that at early stages of human red cell development, prior to terminal differentiation, hematopoietic progenitors exhibited an increased metabolic activity with a significantly higher level of oxidative phosphorylation (OXPHOS). This correlated with the increased generation of αKG and indeed, we found that ectopic αKG directly augmented OXPHOS in these progenitors. However, the terminal differentiation of erythroid precursors, characterized by the loss of mitochondrial mass and membrane potential, was associated with a decreased level of OXPHOS. Notably, ectopic αKG, which did not alter pro-erythroblast erythroid differentiation, severely attenuated terminal differentiation and enucleation. Conversely, an αKG antagonist (dimethyloxalyl glycine, DMOG) did not negatively impact on terminal differentiation or enucleation despite abrogating OXPHOS in erythroblasts.These data suggested that the production of αKG and its subsequent contribution to oxidative phosphorylation perturb red cell enucleation. We therefore downregulated isocitrate dehydrogenase I (IDH1), the cytosolic enzyme that catalyzes the conversion of isocitrate to αKG, by an shRNA approach in an attempt to decrease αKG levels. However, because IDH1 can catalyze both the forward and reverse reactions, its downregulation could also increase αKG levels. Indeed, we found that IDH1 knockdown resulted in a severe attenuation of terminal erythroid differentiation and enucleation. This effect was likely due to an imbalance in substrate availability––both ectopic αKG as well as citrate further decreased polychromatic to orthochromatic erythroblast differentiation and the subsequent enucleation of IDH1-knockdown erythroid precursors. Thus, the present study identifies a crucial role for the αKG metabolite in regulating mitochondrial function and oxidative phosphorylation, processes that are a sine qua non for erythroid precursors at the pro-erythroblast stage. We further show that terminal erythroid differentiation and enucleation requires OXPHOS suppression and the IDH1-mediated enzymatic catalysis of its TCA substrates.To conclude, the results generated during my PhD highlight the dynamic nature of the metabolic networks that regulate the progression of erythroid precursors through the distinct stages of erythroid differentiation
9
Guimarães, Jacqueline da Silva. "Alterações do metabolismo do ferro nas talassemias". Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/60/60135/tde-17042015-113612/.
Pełny tekst źródłaStreszczenie:
As síndromes talassêmicas (?- e ?-talassemia) são as desordens mais comuns e frequentes associadas com eritropoese ineficaz. O desbalanço na produção das cadeias ?- e ?-globinas resulta no comprometimento da produção de eritrócitos, em anemia e aumento de progenitores eritroides no sangue periférico. Enquanto os pacientes homozigóticos afetados por essas desordens demonstram alterações características dos parâmetros relacionados a eritropoese, a relação entre grau de anemia, eritropoese alterada e disfunção do metabolismo de ferro ainda não foram investigados nos indivíduos com ?+-talassemia heterozigótica ou ?+-talassêmia. Duzentos e vinte seis indivíduos (75 do gênero feminino e 151 do gênero masculino) foram recrutados e divididos em 5 grupos: Controle (n=28), doadores de sangue regulares (DSR, n=23), ?+-talassemia heterozigótica (TAT, n=14), ?+-thalassemia (traço ?-talassêmico, TBT, n=20) e ?0-talassemia, (?-talassemia maior, BTM, n=27). As amostras foram analisadas para parâmetros hematológicos (Micros ABX 60); ferro sérico, capacidade total de ligação ao ferro e saturação de transferrina por método colorimétrico (Pointe Scientific, Inc., Canton, MI, USA), ferritina e proteína C-reativa ultra sensível por imunoensaio (Immulite 1000); receptor solúvel de transferrina, eritropoetina, fator de diferenciação do crescimento 15 (R&D Systems) e hepcidina (Intrinsic LifeSciences, La Jolla, CA) por ELISA. As razões sTfR/log ferritina e (hepcidina/ferritina)/sTfR foram calculadas para avaliar o metabolismo do ferro. sTfR/log ferritina pode distinguir depleção dos estoques de ferro de eritropoese deficiente de ferro, enquanto (hepcidina/ferritina)/sTfR pode avaliar os estímulos contrários (disponibilidade de ferro e atividade eritropoética) que controlam a síntese de hepcidina e a absorção de ferro, na ausência de estímulos inflamatórios. Foi demonstrado que TAT teve significativa redução da hepcidina e aumento do receptor solúvel de transferrina, com parâmetros hematológicos relativamente normais. Em contraste, todos os parâmetros hematológicos de TBT foram significativamente diferentes do Controle, incluindo aumento dos níveis do receptor solúvel de transferrina, ferritina, eritropoetina e fator de diferenciação do crescimento 15. Essas alterações em ambos os grupos sugerem um balanço alterado entre eritropoese e metabolismo de ferro. Os índices sTfR/log ferritina e (hepcidina/ferritina)/sTfR estão, respectivamente, aumentado e reduzido comparados ao Controle, proporcional a severidade de cada grupo talassêmico. Em conclusão, destacamos que, pela primeira vez, foram descritas alterações no metabolismo de ferro em indivíduos com ?+-talassemia heterozigótica. Esses dados demonstram que, no contexto da saúde pública, são necessários identificação e acompanhamento dos portadores de ?+-talassemia.The thalassemia syndromes (?- and ?-thalassemia) are the most common and frequent disorders associated with ineffective erythropoiesis. Imbalance of ?- or ?-globin chain production results in impaired red blood cell synthesis, anemia and more erythroid progenitors in the blood stream. While patients affected by these disorders show definitive altered parameters related to erythropoiesis, the relationship between the degree of anemia, altered erythropoiesis and dysfunctional iron metabolism have not been investigated in both carriers of ?-thalassemia and ?-thalassemia. 226 subjects (75 females and 151 males) were recruited to this study and divided in 5 groups: Control (n=28), repeat blood donors (DSR, n=23), ?+-thalassemia heterozygous carriers (TAT, n=14), ?+-thalassemia (?-thalassemia trait, TBT, n=20) and ?0-thalassemia, (?-thalassemia major, BTM, n=27). Samples were tested for hematological parameters (Micros ABX 60); serum iron, total iron binding capacity, and transferrin saturation by the colorimetric method (Pointe Scientific, Inc., Canton, MI, USA), ferritin and high sensitive C-reactive protein by immunoassay (Immulite 1000); soluble transferrin receptor, erythropoietin and growth differentiation factor 15 (R&D Systems) and hepcidin (Intrinsic LifeSciences, La Jolla, CA) by ELISA. Were calculated the ratios sTfR/log ferritin and (hepcidin/ferritin)/sTfR to evaluate iron metabolism. sTfR/log ferritin can distinguish storage iron depletion from iron-deficient erythropoiesis, while (hepcidin/ferritin)/sTfR can be utilized to explore and quantify the opposing forces (i.e. iron availability and erythropoietic activity) regulating hepcidin synthesis and iron absorption in absence of inflammatory stimuli. We demonstrate that TAT have a significantly reduced hepcidin and increased soluble transferrin receptor levels but relatively normal hematological findings. In contrast, TBT have all hematological parameters significantly different from controls, including increased soluble transferrin receptor, ferritin, erythropoietin and growth differentiation factor 15 levels. These changings in both groups suggest an altered balance between erythropoiesis and iron metabolism. The indexes sTfR/log ferritin and (hepcidin/ferritin)/sTfR are respectively increased and reduced relative to controls, proportional to the severity of each thalassemia group. In conclusion, we emphasize that, for the first time in the literature, subjects with heterozygous ?+-thalassemia have altered iron metabolism. Our data demonstrate that within the context of public health, identification and monitoring of patients with ?+-thalassemia are needed.
10
Fertrin, Kleber Yotsumoto 1980. "Aspectos da regulação do metabolismo do ferro nas hemoglobinopatias". [s.n.], 2011. http://repositorio.unicamp.br/jspui/handle/REPOSIP/309315.
Pełny tekst źródłaStreszczenie:
Orientador: Fernando Ferreira CostaTese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-19T02:13:16Z (GMT). No. of bitstreams: 1 Fertrin_KleberYotsumoto_D.pdf: 1904934 bytes, checksum: a74beda8b565fcdc3f59ad37d66ca23e (MD5) Previous issue date: 2011
Resumo: As hemoglobinopatias são distúrbios hereditários em que uma mutação genética leva a alteração da produção normal de hemoglobina, tal como na anemia falciforme e nas talassemias ß. Na maioria dessas doenças, ocorre anemia com necessidade transfusional variável, o que pode acarretar sobrecarga corporal de ferro. Na talassemia ß intermediária, ocorre aumento espontâneo e desproporcional da absorção do ferro, com consequente excesso desse metal mesmo na ausência de transfusões. Com a evolução da terapia transfusional e o aumento da expectativa de vida desses pacientes, o conhecimento sobre a regulação do metabolismo do ferro tornou-se fundamental para melhor controle da sobrecarga de ferro. O principal regulador desse metabolismo é a hepcidina, um polipeptídeo produzido majoritariamente pelo fígado, porém também sintetizado por células do sistema fagocítico-mononuclear, em que seu papel é pouco conhecido. Uma citocina capaz de suprimir a produção de hepcidina é o GDF-15 (fator de crescimento e diferenciação 15). Neste estudo, com a avaliação de amostras de sangue de 103 pacientes com anemia falciforme, talassemia ß intermediária, anemia por deficiência de cobalamina ou outros tipos de anemia, constatou-se que o aumento dos níveis desse fator ocorre tanto em quadros de hemólise crônica quanto na presença de eritropoese ineficaz, constituindo um sinal da medula óssea modulador da absorção de ferro nos estados de aumento da eritropoese. Entretanto, evidenciou-se que a associação de supressão da hepcidina com altos níveis de GDF-15 ocorre nas hemoglobinopatias, mas não nas demais causas de anemia. Na anemia megaloblástica, a ausência de sobrecarga de ferro com níveis normais de hepcidina ao diagnóstico e sua queda durante o tratamento sugerem regulação da hepcidina independente de GDF-15 neste tipo de anemia. A análise da razão hepcidina/ferritina mostrou-se mais fidedigna que os níveis de hepcidina circulante na identificação dos estados em que há propensão a absorção aumentada de ferro por alta atividade eritropoética, e sugerem que o estado inflamatório crônico da anemia falciforme poderia exercer um fator protetor contra sobrecarga de ferro, quando comparados a talassemia intermediária, pela elevação relativa da produção de hepcidina. Além disso, observou-se uma correlação negativa entre a expressão gênica de hepcidina (gene HAMP) em monócitos humanos e os níveis de GDF-15, denotando um provável efeito regulatório semelhante ao descrito em hepatócitos. Não se identificou correlação entre essa expressão nos monócitos e marcadores de sobrecarga de ferro, corroborando a hipótese de a hepcidina ter outra função nessas células, não relacionada diretamente à absorção de ferro. Pacientes com anemia falciforme em uso de hidroxiureia apresentaram maiores níveis de expressão de hepcidina monocítica e obteve-se evidência in vitro de uma ação estimuladora dessa expressão por esse fármaco, caracterizando a hidroxiureia com potencial atividade agonista de hepcidina, de futuro interesse em estudos de sua aplicação clínica nos estados em que exista deficiência monocítica dessa proteína. Trata-se do primeiro estudo avaliando comparativamente hemoglobinopatias e outros tipos de anemia com e sem componente eritropoético ineficaz do ponto de vista dos reguladores da absorção de ferro, além de caracterizar, pela primeira vez, a expressão de hepcidina extra-hepática nos distúrbios da síntese de hemoglobina
Abstract: Hemoglobinopathies are inherited diseases in which a genetic mutation leads to abnormal production of hemoglobin, such as in sickle cell anemia or in the ß-thalassemias. In the majority of these disorders, anemia causes variable degrees of transfusion dependency, which may lead to iron overload. In ß-thalassemia intermedia, an increase in iron absorption occurs spontaneously and regardless from the total body iron stores, generating iron overload even in the absence of repeated transfusions. Owing to advances in transfusion medicine and to the improvement in the overall life expectancy of patients with hemoglobin disorders, further knowledge on the regulation of iron metabolism has become increasingly important for appropriate management of iron overload. The main regulator of iron metabolism is hepcidin, a polypeptide mainly produced by the liver, although its synthesis also occurs in phagocytic-mononuclear cells, in which its role is less known. Growth differentiation factor 15 (GDF-15) is a cytokine capable of downregulating hepcidin production. This study analyzed 103 blood samples from patients with sickle cell anemia, ß-thalassemia intermedia, cobalamin deficiency anemia and other types of anemia, showing elevation of GDF-15 plasmatic levels both in chronic hemolytic states and ineffective erythropoiesis, thus characterizing it as a signalling molecule produced by the bone marrow to stimulate iron absorption in the presence of increased erythropoietic activity. Nevertheless, hepcidin suppression was only associated with high levels of GDF- 15 in the hemoglobinopathies. In megaloblastic anemia, absence of iron overload with normal hepcidin levels, associated with their reduction during treatment, suggest that hepcidin regulation occurs independently from GDF-15 in thie type of anemia. Analysis of hepcidin/ferritin ratio proved to be more reliable to identify patients prone to increased iron absorption due to erythropoietic hyperactivity than hepcidin levels themselves and suggests that the chronic inflammatory state in sickle cell anemia may protect from iron overload by relatively increasing hepcidin levels in comparison to levels found in thalassemia intermedia. Moreover, we found a negative correlation between GDF-15 levels and HAMP monocytic expression, a regulatory mechanism similar to what has been observed in hepatic cell lines. In further analyses of the present study, no correlation between hepcidin expression and iron overload markers was observed in monocytes from patients with hemoglobinopathies, corroborating the hypothesis that the monocytic counterpart of hepcidin could have a different function, unrelated to iron regulation. Patients with sickle cell anemia under hydroxyurea treatment have been shown to present with higher levels of hepcidin expression in monocytes, and a cell culture model managed to demonstrate the upregulating effect of hydroxyurea in vitro, thus highlighting the possibility of exploring this drug in the future as a potential hepcidin agonist and, therefore, as a therapeutic intervention in diseases with impaired monocytic hepcidin production. This is the first study of molecules involved in iron metabolism regulation comparing hemoglobinopathies and other anemia types with and without ineffective erythropoiesis. Furthermore, this is the first characterization of extra-hepatic hepcidin expression in hemoglobin disorders
Doutorado
Biologia Estrutural, Celular, Molecular e do Desenvolvimento
Doutor em Fisiopatologia Medica
Książki na temat "ERYTHROPOIETIC DIFFERENTIATION"
1
Albert, Tyler J., i Erik R. Swenson. The blood cells and blood count. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0265.
Pełny tekst źródłaStreszczenie:
Blood is a dynamic fluid consisting of cellular and plasma components undergoing constant regeneration and recycling. Like most physiological systems, the concentrations of these components are tightly regulated within narrow limits under normal conditions. In the critically-ill population, however, haematological abnormalities frequently occur and are largely due to non-haematological single- or multiple-organ pathology. Haematopoiesis originates from the pluripotent stem cell, which undergoes replication, proliferation, and differentiation, giving rise to cells of the erythroid, myeloid, and lymphoid series, as well as megakaryocytes, the precursors to platelets. The haemostatic system is responsible for maintaining blood fluidity and, at the same time, prevents blood loss by initiating rapid, localized, and appropriate blood clotting at sites of vascular damage. This system is complex, comprising both cellular and plasma elements, i.e. platelets, coagulation and fibrinolytic cascades, the natural intrinsic and extrinsic pathways of anticoagulation, and the vascular endothelium. A rapid, reliable, and inexpensive method of examining haematological disorders is the peripheral blood smear, which allows practitioners to assess the functional status of the bone marrow during cytopenic states. Red blood cells, which are primarily concerned with oxygen and carbon dioxide transport, have a normal lifespan of only 120 days and require constant erythropoiesis. White blood cells represent a summation of several circulating cell types, each deriving from the hematopoietic stem cell, together forming the critical components of both the innate and adaptive immune systems. Platelets are integral to haemostasis, and also aid our inflammatory and immune responses, help maintain vascular integrity, and contribute to wound healing.
2
New Concepts in Blood Formation Cell Generation in Malignant & Benign Tissues: Adult & Embryonic Tissues from Humans & Animals in Chronic Ischemic Con. Diagnostic & Cell Research Institute, 1995.
Znajdź pełny tekst źródłaCzęści książek na temat "ERYTHROPOIETIC DIFFERENTIATION"
1
Dieterlen-Lievre, Francoise. "Respective Roles of Programme and Differentiation Factors during Hemoglobin Switching in the Embryo". W Molecular and Cellular Aspects of Erythropoietin and Erythropoiesis, 127–45. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72652-1_12.
Pełny tekst źródła
2
Zagris, Nikolas. "Cellular Interactions and/or Random Differentiation for the Formation of Erythroid Cells in the Early Chick Embryo". W Molecular and Cellular Aspects of Erythropoietin and Erythropoiesis, 147–63. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72652-1_13.
Pełny tekst źródła
3
Kovilakath, Anna, Safa Mohamad, Farrah Hermes, Shou Zhen Wang, Gordon D. Ginder i Joyce A. Lloyd. "In Vitro Erythroid Differentiation and Lentiviral Knockdown in Human CD34+ Cells from Umbilical Cord Blood". W Erythropoiesis, 259–74. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7428-3_16.
Pełny tekst źródła
4
Oster, W., F. Herrmann, A. Lindemann i R. Mertelsmann. "Experimental and Clinical Evaluation of Erythropoietin". W Growth Factors, Differentiation Factors, and Cytokines, 232–42. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74856-1_17.
Pełny tekst źródła
5
Jaster, Robert, Thomas Bittorf, S. Peter Klinken i Josef Brock. "The Ribosomal S6 Kinase P70S6k Is Involved in the Regulation of The Proliferation Of Hematopoietic Cell Lines But Not In The Induction Of Erythroid Differentiation By Erythropoietin". W Molecular Biology of Hematopoiesis 5, 515–21. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4613-0391-6_62.
Pełny tekst źródła
6
Kumar Gupta, Ashish, i Shashi Bhushan Kumar. "Reticulocytes-Mother of Erythrocytes". W The Erythrocyte - A Unique Cell [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.107125.
Pełny tekst źródłaStreszczenie:
Reticulocytes are immature red blood cells (RBCs) that is seen in the bone marrow after through nuclear extrusion from the orthochromatic normoblasts. They are released into the peripheral blood as mature RBCs, after completion of maturation in the bone marrow. The reticulocyte count reflects the erythropoietic activity of the bone marrow, the rate of reticulocyte delivery from the bone marrow into the peripheral blood, and the rate of reticulocyte maturation. Reticulocyte enumeration is also of value in monitoring bone marrow regenerative activity after chemotherapy or bone marrow transplantation. Manual counting of reticulocytes by light microscopy with supravital dyes for RNA remains the standard method of reticulocyte enumeration. However, automated methods of reticulocyte enumeration developed during the past decade are much more accurate, precise, and cost-effective than manual counting, and are increasingly being performed in the clinical laboratory. The differentiation of the reticulocyte is based on the presence of RNA. The newer techniques provide a variety of reticulocyte related parameters, such as the reticulocyte maturation index and immature reticulocyte fraction, which are not available with light microscopy. These new parameters are under evaluation in the clinical diagnosis and monitoring of hematological disorders.
7
Harrison, Dr Mark. "Haematological system". W Revision Notes for MCEM Part A, 483–85. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199583836.003.0052.
Pełny tekst źródłaStreszczenie:
5.1 Erythropoiesis, 483 5.2 Blood groups, 484 5.3 Coagulation, 485 5.4 Thrombolysis, 485 • Several precursor stages • Occurs in the bone marrow • Earliest recognizable cells are pronormoblasts • Progressive decrease in cell content of RNA during differentiation • Progressive increase in haemoglobin...
8
Papayannopoulou, Thalia, i Anna Rita Migliaccio. "Biology of Erythropoiesis, Erythroid Differentiation, and Maturation". W Hematology, 297–320. Elsevier, 2018. http://dx.doi.org/10.1016/b978-0-323-35762-3.00026-3.
Pełny tekst źródła
9
GOLDWASSER, EUGENE. "Commitment in Blood Cell Differentiation: Erythropoietin as an Instructive Signal". W Control of Animal Cell Proliferation, 93–107. Elsevier, 1987. http://dx.doi.org/10.1016/b978-0-12-123062-3.50009-8.
Pełny tekst źródła
10
Benarroch, Eduardo E. "Growth Factors, Survival, and Regeneration". W Neuroscience for Clinicians, redaktor Eduardo E. Benarroch, 213–30. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780190948894.003.0013.
Pełny tekst źródłaStreszczenie:
Neurotrophic factors and hypoxia-inducible factors participate in fundamental processes including growth, differentiation, survival, and plasticity in the nervous system. They activate downstream cascades that promote protein synthesis and inhibit cell death mechanisms of apoptosis and autophagy. Axonal injury triggers retrograde neurotrophic signaling to the nucleus to regulate transcription of genes involved in axonal repair. Hypoxia induces expression of genes that control angiogenesis, erythropoiesis, and glycolysis. Growth factor and hypoxia-inducible signals are regulated by products of tumor suppressor genes. Excessive activation of these pathways lead to genetic tumor syndromes, many of them associated with epilepsy. Experimental models indicate that growth factors have neuroprotective effects against neurodegeneration. However, several human studies using growth factors administered systemically or via genetic methods have so far failed to show consistent beneficial effects. This has been attributed to inadequate dosing and delivery and enrollment of patients at late stage of disease. Approaches to promote axonal regeneration by targeting are an active area of research.
Streszczenia konferencji na temat "ERYTHROPOIETIC DIFFERENTIATION"
1
Grouix, Brigitte, Lilianne Geerts, Kathy Hince, Nathalie Julien, Marie-Eve Fafard, Liette Gervais, François Sarra-Bournet i in. "Abstract 3534: PBI-1402, a first-in-class erythropoiesis regulating agent, possesses differentiation properties and demonstrates synergistic anticancer activity in combination with chemotherapy". W Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3534.
Pełny tekst źródła